6533b827fe1ef96bd1285db4

RESEARCH PRODUCT

Naringenin Nano-Delivery Systems and Their Therapeutic Applications

Farinaz SaremnejadMehdi ShakibaeiSeid Mahdi JafariAtefeh ZarepourAli ZarrabiAna Cláudia SantosAna MeleroMahzad MotallebiMiguel Pereira-silvaBanafshe AbadiMohammed Bhia

subject

Naringeninnatural productsnaringeninlcsh:RS1-441Pharmaceutical ScienceReview02 engineering and technologyPharmacologylcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compound0302 clinical medicineNutraceuticalSolid lipid nanoparticleflavonoidnutraceuticalsLiposomeChemistryfood and beverages021001 nanoscience & nanotechnologynanomedicineBioavailabilityantioxidants030220 oncology & carcinogenesisdrug deliveryDrug deliveryNanomedicinenanoparticlesNanocarriersbioavailability0210 nano-technology

description

Naringenin (NRG) is a polyphenolic phytochemical belonging to the class of flavanones and is widely distributed in citrus fruits and some other fruits such as bergamot, tomatoes, cocoa, and cherries. NRG presents several interesting pharmacological properties, such as anti-cancer, anti-oxidant, and anti-inflammatory activities. However, the therapeutic potential of NRG is hampered due to its hydrophobic nature, which leads to poor bioavailability. Here, we review a wide range of nanocarriers that have been used as delivery systems for NRG, including polymeric nanoparticles, micelles, liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), nanosuspensions, and nanoemulsions. These nanomedicine formulations of NRG have been applied as a potential treatment for several diseases, using a wide range of in vitro, ex vivo, and in vivo models and different routes of administration. From this review, it can be concluded that NRG is a potential therapeutic option for the treatment of various diseases such as cancer, neurological disorders, liver diseases, ocular disorders, inflammatory diseases, skin diseases, and diabetes when formulated in the appropriate nanocarriers.

yearjournalcountryeditionlanguage
2021-02-01Pharmaceutics
https://doi.org/10.3390/pharmaceutics13020291